Clinical Trial

Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune Diseases

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated December 15, 2025 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
This is an open label, single-site, dose-escalation study in up to 12 participants with relapsed or refractory Neurological Autoimmune Diseases. This study aims to evaluate the safety and efficacy of the treatment with universal CD19/BCMA CAR T-cells.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-04-14; most recent amendment 2025-12-11.
Status change: Not Yet Recruiting → Recruiting 2025-12-11
Trial Details
NCT Number NCT06939166
Lead Sponsor Tianjin Huanhu Hospital
Collaborators: Shanghai Xiniao Biotech Co., Ltd.
Conditions Neuromyelitis Optica Spectrum Disorders, Myasthenia Gravis, Multiple Sclerosis, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Autoimmune Encephalitis
Enrollment 12 participants
Start Date 2025-06-17
Primary Completion 2026-04 (estimated)
Study Completion 2027-10 (estimated)
Updated on ClinicalTrials.gov 2025-12-15